Thus, targeting c-Met and modulating miR-221/222 could be used not only to sensitize NSCLC to TRAIL-inducing apoptosis, but also in the prevention and inhibition of lung cancer [62]. The gene discussed is TNFSF10; the disease is non-small cell lung carcinoma.